Sun Pharma Gets Dcgi Approval For Clinical Trial With Nafamostat In Covid-19 Patients

Sun Pharma Gets Dcgi Approval For Clinical Trial With Nafamostat In Covid-19 Patients

By, Admin 30 May 2020

Sun Pharmaceutical Industries Said On Friday It Has Received Approval From The Drugs Controller General Of India (Dcgi) To Initiate Clinical Trial With Nafamostat Mesilate In Covid-19 Patients.Nafamostat Is Approved In Japan For Improvement Of Acute Symptoms Of Pancreatitis And Treatment Of Disseminated Intravascular Coagulation (Dic).A Group Of Scientists From The University Of Tokyo In Japan And Leibniz Institute For Primate Research In Germany Recently Demonstrated That Nafamostat At Very Low Concentrations Suppresses A Protein (Tmprss2) That The Covid-19 Virus Uses To Enter Human Lung Cellsanother Group From Institut Pasteur In South Korea Also Published Data Comparing Antiviral Efficacy Of 24 Drugs And Nafamostat Against Sarscov-2 In In-Vitro Studies In Human Lung Epithelial Derived Cells.In This Research, Nafamostat Was Found To Be The Most Potent Drug And Was Able To Inhibit Virus Entry At Very Low Concentrations, Consistent With Findings From Japan And German Labs.Globally, There Are Three Clinical Trials Currently Underway To Test Nafamostat In Covid-19 Patients. Thesetrials Are Being Led By The University Of Tokyo Hospital In Japan, Gyeongsang National University Hospital In South Korea, And A Collaborative Trial By University Hospital At Padova In Italy, University Of Zurich Inswitzerland And Yokohoma City University In Japan.More On Covid-19Coronavirus Pandemic: Complete CoverageLockdown 4.0: What'S Allowed And What'S Not In The Three ZonesIt'S Time To Mask Up And Stay Safe: Join Toi'S #Maskindia CampaignMha'S Guidelines For Home IsolationTrust The Newspaper For Your Daily Verified NewsConsidering The Pandemic Situation And Urgent Need For Newer Treatment Options, Sun Pharma Plans Toinitiate The Clinical Trials At The Earliest. The Company Has Initiated Manufacturing Of Both, The Active Pharma Ingredient And The Finished Product Of Nafamostat In India, Using Technology From Its Subsidiary, Pola Pharma Japan.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!